60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

* All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests * Four of five completed patients (80%) were negative on highly sensitive post-treatment NAT testing * Results reinforce favorable retreatment-free outcomes reported with tafenoquine–atovaquone regimens * Two additional patients remain on treatment, bringing total enrollment to seven; study remains open pending potential discussions with FDA WASHINGTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced clinical and molecular results from the first five patients to complete treatment with tafenoquine-containing combination regimens in the Company’s expanded access study of relapsing babesiosis in immunosuppressed patients (NCT06478641).